EDX Medical Group Plc, together with its subsidiaries, provides diagnostic products and solutions in the United Kingdom. It operates in two segments, Medical Goods and Medical Services. The company offers Caris MI Profile, a tumour profiling platform; cResponse, a platform the assess and predicts the effectiveness of single and multi drug chemotherapy; MI Tumor Seek, a next generation sequencing based tumour profiling service; Caris Assure, a blood based comprehensive molecular profiling designed for patients with previously diagnosed solid tumours when tissue biopsy is not feasible; and TC100, a cancer testing service combining M371 microRNA testing with classical serum tumour markers. It also provides M371 Test, a blood-based microRNA test for diagnosing and monitoring testicular germ cell tumours; Prostate cancer super test; BC95, a Bowel Cancer Testing Service; EarlyTect, a stool DNA test for colorectal cancer screening; and Hereditary Cancer Testing, an NGS test that identifies inherited variants in cancer-predisposition genes. In addition, the company offers acute respiratory distress and pneumonia ICU test; multiple biomarker 5FU pharmacogenomic test; and point of care multiplex sepsis test. Further, it provides laboratory services, including polymerase chain reaction test is used to identify the genetic material of a particular organism, such as a virus. Additionally, the company is involved in design, development, and manufacture of IVD reagants; and research and development on biotechnology. Its products are used for cancer, cardiovascular diseases, and infectious diseases. The company was formerly known as TECC Capital PLC and changed its name to EDX Medical Group Plc in November 2022. EDX Medical Group Plc was incorporated in 2021 and is headquartered in Cambridge, the United Kingdom.